These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3140452)

  • 1. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
    Chatenoud L
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
    [No Abstract]   [Full Text] [Related]  

  • 2. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
    Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
    [No Abstract]   [Full Text] [Related]  

  • 3. [In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
    Chatenoud L; Bach JF
    Nephrologie; 1987; 8(3):95-8. PubMed ID: 3309702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A.
    Widmer U; Frei D; Keusch G; Burger HR; Largiader F; Binswanger U
    Transplant Proc; 1988 Oct; 20(5 Suppl 6):90-5. PubMed ID: 3140454
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical development of Orthoclone OKT3.
    Cosimi AB
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
    McLigeyo SO; Notghi A; Anderton JL; Dick J
    East Afr Med J; 1990 Sep; 67(9):667-73. PubMed ID: 2123786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
    Monaco A; Goldstein G; Barnes L
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
    Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunologic monitoring in OKT3-treated kidney graft recipients.
    Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
    Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
    [No Abstract]   [Full Text] [Related]  

  • 10. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection.
    Georgitis JW; Browning MC; Steiner D; Lorentz WB
    Ann Allergy; 1991 Apr; 66(4):343-7. PubMed ID: 1901692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
    Birkeland SA; Bach JF; Chatenoud L; Jørgensen KA; Strate M; Elbirk A; Rohr N; Svendsen V
    Transplant Proc; 1990 Feb; 22(1):221-2. PubMed ID: 2106740
    [No Abstract]   [Full Text] [Related]  

  • 12. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.
    Colvin RB; Preffer FI
    Clin Lab Med; 1991 Sep; 11(3):693-714. PubMed ID: 1934971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A U.S. clinical study of Orthoclone OKT3 in renal transplantation.
    Norman DJ; Shield CF; Barry J; Henell K; Funnell MB; Lemon J
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):21-7. PubMed ID: 3105136
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversing cardiac transplant rejection with Orthoclone OKT3.
    Dault LA; Nagy CS; Collins JA
    Am J Nurs; 1989 Jul; 89(7):953-5. PubMed ID: 2500020
    [No Abstract]   [Full Text] [Related]  

  • 15. The clinical role of OKT3.
    Norman DJ
    Cardiol Clin; 1990 Feb; 8(1):97-105. PubMed ID: 2407364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Orthoclone OKT3 (Muromonab CD3)--the indications for and manner of its use. Side effects and their prevention].
    Filev A; Kumanov Kh; Slavov Ch; Tsvetkov M
    Khirurgiia (Sofiia); 1989; 42(6):80-2. PubMed ID: 2517512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use.
    Emmons C; Hunsicker LG
    Iowa Med; 1987 Feb; 77(2):78-82. PubMed ID: 3557906
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection.
    Norman DJ; Shield CF; Henell KR; Kimball J; Barry JM; Bennett WM; Leone M
    Transplantation; 1988 Oct; 46(4):523-9. PubMed ID: 3140448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In situ antigenic modulation of human graft-infiltrating T cells is induced by OKT3 treatment.
    Caillat-Zucman S; Legendre C; Noel LH; Bach JF; Kreis H; Chatenoud L
    Transplant Proc; 1990 Aug; 22(4):1782. PubMed ID: 2143860
    [No Abstract]   [Full Text] [Related]  

  • 20. Review and preview of anti-T-cell antibodies.
    Helderman JH
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.